Article
Neurosciences
Eleonora Cocco, Paola Fadda
Summary: Multiple sclerosis is a complex disorder with a wide range of symptoms, categorized as visible and invisible. Fatigue is a common symptom in MS patients that significantly impacts daily living and quality of life, and it does not improve with rest.
EXPERIMENTAL NEUROLOGY
(2022)
Article
Immunology
Nicolas Fissolo, Laura Calvo-Barreiro, Herena Eixarch, Ursula Boschert, Luisa M. Villar, Lucienne Costa-Frossard, Mireia Ferrer, Alex Sanchez, Eva Borras, Eduard Sabido, Carmen Espejo, Xavier Montalban, Manuel Comabella
Summary: This study characterized the transcriptomic and proteomic profiles induced by cladribine in blood cells, and identified potential treatment response biomarkers to cladribine in patients with multiple sclerosis.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Clinical Neurology
Clara Grazia Chisari, Eleonora Sgarlata, Sebastiano Arena, Simona Toscano, Maria Luca, Francesco Patti
Summary: Evidence has shown the involvement of B cells in multiple sclerosis (MS) pathogenesis, with B-cell-depleting therapies like rituximab (RTX) being considered as a treatment option. While RTX has demonstrated efficacy in reducing inflammation, relapses, and new brain lesions in RRMS patients, its off-label use varies among Northern European countries. The review highlights RTX as a potential alternative treatment option for MS management, especially amidst the COVID-19 pandemic and concerns about infection risks.
JOURNAL OF NEUROLOGY
(2022)
Review
Immunology
Haoyang Duan, Yuling Jing, Yinghua Li, Yawen Lian, Jianfang Li, Zhenlan Li
Summary: Multiple sclerosis is a slowly progressive disease that can be delayed by immunosuppressants and other drugs, but patients usually experience various neurological deficit symptoms. Professional rehabilitation treatment can reduce dysfunction, improve neurological function, and reduce burdens. New rehabilitation technologies have further established the advantages of rehabilitation therapy in multiple sclerosis treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Aigli G. Vakrakou, Maria-Evgenia Brinia, Anastasia Alexaki, Evangelos Koumasopoulos, Panos Stathopoulos, Maria-Eleftheria Evangelopoulos, Leonidas Stefanis, Christine Stadelmann-Nessler, Constantinos Kilidireas
Summary: The expanded treatment landscape in relapsing-remitting MS has provided highly effective treatment options, but also increased complexity in managing disease- or drug-related events. Proper decision-making requires thorough understanding of MS immunobiology and underlying mechanisms. The immune system is highly adaptable, but treatments can have harmful effects. Clinicians need to make appropriate clinical decisions for atypical relapses and consider switching therapies for the multiple faces of MS.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Sabrina Haben, Andrea Ciplea, Marianne Tokic, Nina Timmesfeld, Sandra Thiel, Ralf Gold, Annette Magdalene Langer-Gould, Kerstin Hellwig
Summary: This study aimed to assess the association between four different postpartum strategies and relapse risk during the first 6 months postpartum. The results showed that early treatment with natalizumab/fingolimod reduced the hazard of postpartum relapse from month 3, but did not diminish the hazard of early postpartum relapse. Therefore, an early postpartum treatment strategy should be determined well before delivery for women with active multiple sclerosis.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Food Science & Technology
Federica Novarella, Antonio Carotenuto, Paolo Cipullo, Rosa Iodice, Emanuele Cassano, Antonio Luca Spiezia, Nicola Capasso, Maria Petracca, Fabrizia Falco, Carmine Iacovazzo, Giuseppe Servillo, Roberta Lanzillo, Vincenzo Brescia Morra, Marcello Moccia
Summary: This study aimed to evaluate the rate of discontinuation of botulinum toxin (BT) treatment for spasticity in multiple sclerosis (MS) patients and its correlation with MS, spasticity, and injection variables. The study findings suggest that discontinuation of BT treatment is associated with concomitant MS-related issues and cognitive impairment. Shortening the interval between injections can reduce long-term discontinuation.
Article
Clinical Neurology
Brit Ellen Rod, Oivind Torkildsen, Kjell-Morten Myhr, Lars Bo, Stig Wergeland
Summary: Our study found minimal transfer of rituximab into breast milk in nursing mothers, and the levels of rituximab in infant serum were difficult to detect. The B cell counts in infants were unaffected.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Kamari Christina, Galanakis Emmanouil, Raissaki Maria, Briassoulis George, Vlachaki Georgia, Vorgia Pelagia
Summary: This article presents a case of multiple sclerosis in a 12.5-year-old boy, who was diagnosed using various brain imaging techniques and treated with a combination of aggressive treatment and immunomodulatory therapy, resulting in stable clinical outcomes.
NEUROLOGICAL SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Weipeng Wei, Denglei Ma, Lin Li, Lan Zhang
Summary: Multiple sclerosis is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system, with no complete cure currently available but drugs that can slow down its progression. Traditional therapies mainly focus on disease-modifying drugs to control severity, while new drugs and treatment strategies are being developed.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Pasquale Picone, Domenico Nuzzo
Summary: In recent years, studies have shown that mitochondrial aberration plays a crucial role in mediating axonal degeneration in Multiple Sclerosis (MS), along with inflammation and demyelination. This has led to the recognition of mitochondria as a potential therapeutic target for MS. Mitochondrial transplantation has emerged as a new approach for treating various diseases, including neurodegenerative diseases. In this hypothesis, the authors propose mitochondrial transplantation as a new, potentially applicable strategy to counteract axonal degeneration in multiple sclerosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Ivan Adamec, Ivan Jovanovic, Magdalena Krbot Skoric, Mario Habek
Summary: This study reports on 6 patients with MS who experienced disease activity after alemtuzumab treatment, but remained relapse-free and stable after subsequent treatment with cladribine for up to 2 years. None of the patients experienced infections or malignancies during the follow-up period.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Krzysztof Selmaj, Bruce A. C. Cree, Michael Barnett, Alan Thompson, Hans-Peter Hartung
Summary: This review addresses the changes in treating patients with multiple sclerosis, emphasizing the benefits of initiating treatment with high-efficacy agents. Recent studies have shown that early treatment with high-efficacy agents leads to lower relapse rates and reduced disability progression.
JOURNAL OF NEUROLOGY
(2023)
Review
Medicine, Research & Experimental
Zeinab Jan, Samaneh Mollazadeh, Khalil Abnous, Seyed Mohammad Taghdisi, Abolghasem Danesh, Mohammad Ramezani, Mona Alibolandi
Summary: Multiple sclerosis is a neurodegenerative disease of the central nervous system that requires timely and effective management. Nanoscale platforms offer practical and ideal approaches to improve conventional therapies and have potential in the diagnosis and treatment of MS.
MOLECULAR PHARMACEUTICS
(2022)
Article
Neurosciences
Catherine Stratton, Areti Vassilopoulos, J. Nicholas Brenton, Kirsten Potter, Wendy Vargas, Heather Rumm, Andrea Bartels, Mary Bailey, Charles Odonkor, Sharon Stoll, E. William T. Zempsky, E. Ann Yeh, Naila Makhani
Summary: This study aimed to develop an interdisciplinary interim guideline for the assessment and management of pain in children with MS. Literature on pain in children with MS is scarce, and further studies are needed to assess the implementation of these guidelines in clinical settings.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Neurosciences
Jeffrey M. Greeson, David R. Gettes, Sergei Spitsin, Benoit Dube, Tami D. Benton, Kevin G. Lynch, Steven D. Douglas, Dwight L. Evans
BIOLOGICAL PSYCHIATRY
(2016)
Article
Cell Biology
Sergei Spitsin, John Meshki, Angela Winters, Florin Tuluc, Tami D. Benton, Steven D. Douglas
JOURNAL OF LEUKOCYTE BIOLOGY
(2017)
Article
Virology
Danielle Fortuna, Ana Maria Cardenas, Erin H. Graf, Larry A. Harshyne, D. Craig Hooper, Michael Prosniak, John Shields, Mark T. Curtis
JOURNAL OF CLINICAL VIROLOGY
(2017)
Article
Immunology
Emily K. Bongiorno, Samantha A. Garcia, Sami Sauma, D. Craig Hooper
JOURNAL OF IMMUNOLOGY
(2017)
Editorial Material
Cell Biology
Steven D. Douglas, Sergei Spitsin
JOURNAL OF LEUKOCYTE BIOLOGY
(2017)
Review
Cell Biology
Sergei Spitsin, Vasiliki Pappa, Steven D. Douglas
JOURNAL OF LEUKOCYTE BIOLOGY
(2018)
Article
Neurosciences
Samantha A. Garcia, Aurore Lebrun, Rhonda B. Kean, D. Craig Hooper
JOURNAL OF NEUROVIROLOGY
(2018)
Article
Multidisciplinary Sciences
Danielle Fortuna, D. Craig Hooper, Amity L. Roberts, Larry A. Harshyne, Michelle Nagurney, Mark T. Curtis
Article
Medicine, Research & Experimental
Sergei Spitsin, Bruce C. Schnepp, Mary J. Connell, Tehui Liu, Christine M. Dang, Vasiliki Pappa, Richard Tustin, Annemarie Kinder, Philip R. Johnson, Steven D. Douglas
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
(2020)
Article
Immunology
Michael Prosniak, Larry A. Harshyne, Jonathan Gorky, Mark T. Curtis, Lawrence C. Kenyon, James S. Schwaber, Aurore Lebrun, Rhonda B. Kean, David W. Andrews, D. Craig Hooper
Summary: Patients with grade III anaplastic astrocytomas (AA) can be categorized into distinct immune bias profiles based on the presence or absence of mutations in isocitrate dehydrogenase (IDH). Two different immune biases were identified in patients with different IDH mutational status, with type 2 bias more common in IDH wild-type AA and type 1 bias more common in patients with IDH1R132H mutation. Additionally, the patient's immune profile was found to be more closely associated with tumor vascular enhancement on imaging rather than IDH mutational status.
JOURNAL OF IMMUNOLOGY
(2021)
Article
Oncology
Bo Yan, D. Craig Hooper, Zhiyong Yuan, Changli Wang, Yulong Chen, Bo Lu
Summary: This study aimed to determine whether humoral immunity contributed to observed cardiac tissue damage in concurrent cardiac irradiation and PD-1 blockade. The study found that the presence of cardiac autoantibodies played a key role in the resulting cardiotoxicity.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Virology
Aurore Lebrun, Rhonda B. Kean, D. Craig Hooper
Article
Medicine, Research & Experimental
Sergei Spitsin, Pablo Tebas, Jeffrey S. Barrett, Vasiliki Pappa, Deborah Kim, Deanne Taylor, Dwight L. Evans, Steven D. Douglas
Article
Biochemistry & Molecular Biology
Erika M. Palmieri, Alessio Menga, Aurore Lebrun, Douglas C. Hooper, D. Allan Butterfield, Massimiliano Mazzone, Alessandra Castegna
ANTIOXIDANTS & REDOX SIGNALING
(2017)
Article
Immunology
Florin Tuluc, Sergei Spitsin, Nancy B. Tustin, Jennifer B. Murray, Richard Tustin, Laura A. Schankel, Andrew Wiznia, Sharon Nachman, Steven D. Douglas
AIDS RESEARCH AND HUMAN RETROVIRUSES
(2017)